P763: Role of quality of life in patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Kaltenbach, T.(1)*;Schulte, L.A.(1);Kranzeder, A.(2);Klaus, J.(1);Sularz, M.(1);
(1)Innere Medizin I, Uniklinik Ulm, Ulm, Germany;(2)Psychosomatische Klinik, Uniklinik Ulm, Ulm, Germany;
P764: Effectiveness and safety of COVID-19 Vaccine among Patients with Inflammatory Bowel Disease: A medical center hospital-based study in central TaiwanECCO’23 CopenhagenYear: 2023
Authors: Wu, Y.H.(1)*;Chou, J.W.(2);Huang, P.J.(1);Wang, C.P.(1);Cheng, K.S.(1);
(1)China Medical University Hospital, Center for Digestive Medicine- Department of Internal Medicine, Taichung, Taiwan;(2)China Medical University Hospital, Department of Internal Medicine, Taichung City, Taiwan;
P766: Practical application of evidence-based dietary therapy into inflammatory bowel disease care shows high patient satisfaction, compliance, and efficacy. The Delectable ProgramECCO’23 CopenhagenYear: 2023
Authors: Russell, E.(1,2);Trakman, G.(1,2,3);Hamilton, A.L.(1,2);Wilson-O'Brien, A.(1,2);Hendricks, N.(4);Simmance, N.(4);Thompson, E.(4);Niewiadomski, O.(1)*;Kamm, M.(1,2);
(1)St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)La Trobe University, Department of Sport- Nutrition and Dietetics, Melbourne, Australia;(4)St Vincent's Hospital, Nutrition Department, Melbourne, Australia;
P767: Intestinal ultrasonography predicts short term clinical remission in patients with moderate-to-severe ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Zorzi, F.(1);De Cristofaro, E.(1);Abreu, M.T.(2);Montesano, L.(1);Cuccagna, E.(1);Essofi, S.(1);Biancone, L.(1);Monteleone , G.(1);Calabrese, E.(1)*;
(1)University of Rome Tor Vergata, Gastroenterology Unit- Department of Systems Medicine, Rome, Italy;(2)University of Miami Miller School of Medicine, Crohn's & Colitis Center- Department of Medicine, Miami, United States;
P768: The prevalence and risk factors for malignancies in patients with inflammatory bowel disease in Crete : a case control studyECCO’23 CopenhagenYear: 2023
Authors: Foteinogiannopoulou, K.(1)*;Nicolaou, P.(2);Mala, A.(3);Theodoraki, E.(1);Orfanoudaki, E.(1);Theodoropoulou, A.(2);Karmiris, K.(2);Koutroubakis, I.(1);
(1)University Hospital of Heraklion, Gastroenterology Department, Heraklion, Greece;(2)Venizeleio General Hospital, Gastroenterology Department, Heraklion, Greece;(3)University Hospital of Heraklion, Oncology Department, Heraklion, Greece;
P769: Randomised feasibility study of preoperative medical nutrition therapy in adults undergoing surgery for Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Wall, C.(1)*;Glyn, T.(2);Rowbotham, D.(3);Haines, M.(4);Bissett, I.(5);Eglinton, T.(2,6);Gearry, R.(1,7);
(1)University of Otago, Department of Medicine, Christchurch, New Zealand;(2)Te Whatu Ora Waitaha Canterbury, Surgery Department, Christchurch, New Zealand;(3)Te Whatu Ora Te Toku Tumai Auckland, Department of Gastroenterology and Hepatology, Auckland, New Zealand;(4)Te Whatu Ora Waikato, Department of Gastroenterology, Hamilton, New Zealand;(5)University of Auckland, Department of Surgery, Auckland, New Zealand;(6)University of Otago, Department of Surgery, Christchurch, New Zealand;(7)Te Whatu Ora Waitaha Canterbury, Gastroenterology Department, Christchurch, New Zealand;
P770: Autologous regulatory T cell transfer in patients with refractory ulcerative colitis: Interim report of a phase 1, dose-escalation trialECCO’23 CopenhagenYear: 2023
Authors: Voskens, C.(1)*;Stoica, D.(1);Rosenberg, M.(1);Weidinger, C.(2);Vitali, F.(3);Zundler, S.(3);Ganslmayer, M.(3);Wiesinger, M.(1);Wunder, J.(3);Kummer, M.(1);Siegmund, B.(2);Schnoy, E.(4);Rath, T.(3);Hartmann, A.(5);Hackstein, H.(6);Schuler-Thurner, B.(1);Berking, C.(1);Schuler, G.(1);Atreya, R.(3);Neurath, M.F.(3);
(1)University Hospital Erlangen- Deutsches Zentrum für Immuntherapie DZI- Friedrich-Alexander University Erlangen-Nürnberg, Department of Dermatology, Erlangen, Germany;(2)Charité - Universitätsmedizin Berlin- corporate member of Freie Universität Berlin- Humboldt-Universität zu Berlin- Campus Benjamin Franklin, Medical Department- Division of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(3)University Hospital Erlangen- Deutsches Zentrum für Immuntherapie DZI- Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany;(4)University Hospital Augsburg, Department of Gastroenterology, Augsburg, Germany;(5)University Hospital Erlangen- Friedrich-Alexander University Erlangen- Nürnberg, Department of Pathology, Erlangen, Germany;(6)University Hospital Erlangen- Friedrich-Alexander University Erlangen- Nürnberg, Department of Transfusion Medicine, Erlangen, Germany;
P771: Biologics versus azathioprine in steroid-dependent ulcerative colitis: results from the A.U.R.O.R.A. databaseECCO’23 CopenhagenYear: 2023
Authors: Cassinotti, A.(1)*;Saibeni, S.(2);De Silvestri, A.(3);Mezzina, N.(4);Di Paolo, D.(5);Alimenti, E.(2);Annunziata, M.L.(5);Albertini Petroni, G.(5);Segato, S.(1);Canova, L.(6);Italia, A.(7);Zammarchi, I.(8);Casini, V.(9);Ricci, C.(8);Di Sabatino, A.(10);Invernizzi, P.(11);Maconi, G.(12);Pace, F.(9);Pagano, N.(7);Segato, S.(1);Bezzio, C.(2);Pastorelli, L.(13);Vecchi, M.(14);Ardizzone, S.(12);
(1)ASST Sette Laghi, Gastroenterology and Digestive Endoscopy Unit, Varese, Italy;(2)ASST Rhodense, Gastroenterology Unit, Rho, Italy;(3)Fondazione IRCCS Policlinico San Matteo, Clinical Epidemiology and Biometry, Pavia, Italy;(4)Department of Biochemical and Clinical Sciences "L. Sacco"- ASST Fatebenefratelli Sacco, Gastroenterology Unit, Milano, Italy;(5)Policlinico San Donato, Gastroenterology Unit, San Donato Milanese, Italy;(6)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milano, Italy;(7)Ospedale Maggiore della Carità, Gastroenterology Unit, Novara, Italy;(8)ASST Ospedali Civili Brescia, Gastroenterology Unit, Brescia, Italy;(9)ASST Bergamo Est, Gastroenterology Unit, Seriate, Italy;(10)Fondazione IRCCS Policlinico San Matteo- University of Pavia, Department of Internal Medicine, Pavia, Italy;(11)San Gerardo Hospital, Division of Gastroenterology and Center for Autoimmune Liver Diseases- University of Milano-Bicocca, Monza, Italy;(12)Department of Biochemical and Clinical Sciences "L. Sacco"- University of Milan- ASST Fatebenefratelli Sacco, Gastroenterology Unit, Milano, Italy;(13)ASST Santi Paolo e Carlo- Ospedale San Paolo- University of Milan- Policlinico San Donato, Gastroenterology and Hepatology Unit, Milano- San Donato Milanese, Italy;(14)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico- University of Milan, Gastroenterology and Endoscopy Unit, Milano, Italy;AURORA STUDY GROUP
P772: Association of histological remission with long-term clinical outcomes in patients with ulcerative colitis: a multi-national retrospective study with centralized histological assessmentECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1,2)*;Armuzzi, A.(3,4);Pai, R.K.(5);Sun, D.(6);Li, Y.(7);Bassel, M.(8);Brett, N.R.(8);Bojic, D.(9);
(1)Western University, Department of Medicine, London, Canada;(2)Western University, Department of Epidemiology and Biostatistics, London, Canada;(3)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(4)Humanitas University, Department of Biomedical Sciences, Milan, Italy;(5)Mayo Clinic Arizona, Laboratory Medicine and Pathology, Scottsdale, United States;(6)Genentech- a Member of the Roche Group, Product Development Data Sciences, South San Francisco, United States;(7)F. Hoffman-La Roche AG, Product Development Data Sciences, Basel, Switzerland;(8)PPD- Part of Thermo Fisher Scientific, Real-World Evidence, Montreal, Canada;(9)F. Hoffman-La Roche AG, Product Development Medical Affairs, Basel, Switzerland;
P773: Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatmentECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Colombel, J.F.(2);Chiorean, M.V.(3);Ghosh, S.(4);Jain, A.(5);Lawlor, G.(5);Osterman, M.T.(5);Wu, H.(5);Canavan, J.B.(5);Rubin, D.T.(6);
(1)University of Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(2)Icahn School of Medicine of Mount Sinai, Gastroenterology, New York, United States;(3)Swedish Gastroenterology, Gastroenterology, Issaquah, United States;(4)University of Birmingham, Immunology and Immunotherapy, Birmingham, United Kingdom;(5)Bristol Myers Squibb, Clinical Research, Princeton, United States;(6)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;
P774: Maintenance treatment with vedolizumab in children with Inflammatory Bowel Disease: follow-up results from the prospective multicenter VEDOKIDS studyECCO’23 CopenhagenYear: 2023
Authors: Atia, O.(1); Shavit-Brunschwig, Z.(1);Quteineh, A.(1); Lev-Tzion, R.(1); Stein, R.(2);Broide, E.(3);Urlep, D.(4);Hyams, J.(5);Aloi, M.(6);Shouval, D.S.(7);Assa, A.(1);Hussey, S.(8);Markowitz, J.(9);Yerushalmy, A.(10);Miele, E.(11);Russell, R.K.(12);Turner, D.(1)*;
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Israel., Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Children's Hospital of Philadelphia, Children's Hospital of Philadelphia, Philadelphia, United States;(3)Shamir Medical Center, Shamir Medical Center, Be'er Ya'akov, Israel;(4)University Children's Hospital of the University Medical Centre Ljubljana, University Children's Hospital of the University Medical Centre Ljubljana, Ljubljana, Slovenia;(5)Connecticut Children's Medical Center- Hartford- CT, Connecticut Children's Medical Center- Hartford- CT, Connecticut, United States;(6)Sapienza University of Rome, Sapienza University of Rome, Rome, Italy;(7)Schneider Children's Medical Center of Israel, Schneider Children's Medical Center of Israel, Petach Tikva, Israel;(8)National Children's Research Center, National Children's Research Center, Dublin, Ireland;(9)The Feinstein Institute for Medical Research, The Feinstein Institute for Medical Research, Northwell, United States;(10)Tel Aviv Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;(11)Università degli Studi di Napoli "Federico II", Università degli Studi di Napoli "Federico II", Napoli, Italy;(12)The Royal Hospital for Children & Young People, The Royal Hospital for Children & Young People, Edinburgh, United Kingdom;
P775: Disease activity and treatment patterns of newly diagnosed adult patients with Crohn's disease in Japan: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD)ECCO’23 CopenhagenYear: 2023
Authors: Shinzaki, S.(1)*;Matsuoka, K.(2);Fujii, T.(3);Okamoto, R.(3);Yamada, A.(2);Kunisaki, R.(4);Matsuura, M.(5);Watanabe, K.(1);Shiga, H.(6);Takatsu, N.(7);Bamba, S.(8);Mikami, Y.(9);Yamamoto, T.(10);Shimoyama, T.(10);Motoya, S.(11);Torisu, T.(12);Kobayashi, T.(13);Ohmiya, N.(14);Saruta, M.(15);Matsuda, K.(16);Matsumoto, T.(17);Nakase, H.(18);Maemoto, A.(19);Murata, Y.(20);Yoshigoe, S.(20);Tsuchiya, H.(20);Hisamatsu, T.(5);
(1)Hyogo Medical University, Center for Inflammatory Bowel Disease- Division of Gastroenterology and Hepatology- Department of Internal Medicine, Nishinomiya- Hyogo, Japan;(2)Toho University Sakura Medical Center, Department of Internal Medicine, Sakura- Chiba, Japan;(3)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Bunkyo-ku- Tokyo, Japan;(4)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Minami-ku- Yokohama- Kanagawa, Japan;(5)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Mitaka- Tokyo, Japan;(6)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai- Miyagi, Japan;(7)Fukuoka University Chikushi Hospital, Department of Inflammatory bowel disease center, Chikushino- Fukuoka, Japan;(8)Shiga University of Medical Science, Division of Digestive Endoscopy, Otsu- Shiga, Japan;(9)Keio University, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Shinjiku-ku- Tokyo, Japan;(10)Yokkaichi Hazu Medical Center, Department of Surgery and Inflammatory Bowel Disease Center, Yokkaichi- Mie, Japan;(11)Sapporo-Kosei General Hospital, IBD Center- Hokkaido Preventive Welfare Federation of Agricultural Cooperative, Sapporo- Hokkaido, Japan;(12)Kyushu University, Department of Medicine and Clinical Science- Graduate School of Medical Sciences, Higashi-ku- Fukuoka, Japan;(13)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Minato-ku- Tokyo, Japan;(14)Fujita Health University School of Medicine, Department of Advanced Endoscopy, Toyoake- Aichi, Japan;(15)The Jikei University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Minato-ku- Tokyo, Japan;(16)Toyama Prefectural Central Hospital, Department of Gastroenterology, Toyama- Toyama, Japan;(17)Iwate Medical University, Division of Gastroenterology- Department of Internal Medicine- School of Medicine, Morioka- Iwate, Japan;(18)Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo- Hokkaido, Japan;(19)Sapporo Higashi Tokushukai Hospital, IBD Center, Sapporo- Hokkaido, Japan;(20)Janssen Pharmaceutical K.K., Medical Affairs Division, Chiyoda-ku- Tokyo, Japan;
P776: Polymeric exclusive enteral nutrition induces biochemical remission in adults with active Crohn's Disease irrespective of disease location or concomitant steroid useECCO’23 CopenhagenYear: 2023
Authors: Kuo, H.(1)*;Tognolini, K.(2);Willmann, L.(1);Haig, A.(1);Subhaharan, D.(1);Mutsekwa, R.(2);Shukla, D.(1);Moattar, H.(1);Dorrington, A.(1);Ishaq, N.(1);Bhullar, M.(1);Edwards, J.(1);Mohsen, W.(1);Kakkadasam Ramaswamy, P.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Gold Coast, Australia;(2)Gold Coast University Hospital, Department of Nutrition and Food Services, Gold Coast, Australia;Gold Coast Inflammatory Bowel Diseases Research Group
P777: Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sitesECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1)*;Rubin, D.(2);Weber, C.(3);Adsul, S.(4);Freire, M.(4);Biedermann, L.(5);Koelzer, V.(6);Bressler, B.(7);Xiong, W.(8);Niess, J.(9);Matthias Matter, M.M.(9);Kopylov, U.(10);Barshack, I.(11);Mayer, C.(11);Magro, F.(12);Carneiro, F.(13);Maharshak, N.(14);Greenberg, A.(15);Hart, S.(16);Dehmeshki, J.(17);Kubassova, O.(16);
(1)Nancy University Hospital, Gastroenterology, Nancy, France;(2)University of Chicago Medicine, Section of Gastroenterology- Hepatology and Nutrition, Chicago- IL, United States;(3)University of Chicago Medicine, Department of Pathology, Chicago- IL, United States;(4)Takeda, Takeda, Zurich, Switzerland;(5)University Hospital of Zurich, University of Zürich, Zurich, Switzerland;(6)University Hospital Zürich, Institute of Pathology and Molecular Pathology, Zurich, Switzerland;(7)University of British Columbia, Division of Gastroenterology, Vancouver- BC, Canada;(8)University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver- BC, Canada;(9)University of Basel, University Hospital Basel, Basel, Switzerland;(10)Chaim Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(11)Chaim Sheba Medical Center, Institute of Pathology, Ramat Gan, Israel;(12)Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal;(13)Centro Hospitalar Universitário de São João, Department of Pathology, Porto, Portugal;(14)Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(15)Tel Aviv Medical Center, Institute of Pathology, Tel Aviv, Israel;(16)Image Analysis Group, Image Analysis Group, London, United Kingdom;(17)Image Analysis Group, Kingston University, London, United Kingdom;
P778: Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)ECCO’23 CopenhagenYear: 2023
Authors: García, M.J.(1)*;Riestra, S.(2);Amiot, A.(3);Julsgaard, M.(4);García de la Filia, I.(5);Calafat, M.(6);Aguas, M.(7);de la Peña, L.(8);Roig-Ramos, C.(9);Caballol, B.(10);Casanova, M.J.(11);Farkas, K.(12);Boysen, T.(13);Bujanda, L.(14);Cuarán, C.(15);Dobru, D.(16);Fousekis, F.(17);Gargallo-Puyuelo, C.J.(18);Savarino, E.(19);Calvet, X.(20);Huguet, J.M.(21);Kupcinskas, L.(22);López-Cardona, J.(23);Raine, T.(24);van Oostrom, J.(25);P. Gisbert*, J.(11);Chaparro*, M.(11);
(1)Hospital Universitario Marqués de Valdecilla- IDIVAL- Universidad de Cantabria, Gastroenterology and Hepatology, Santander- Cantabria, Spain;(2)Hospital Universitario Central de Asturias- Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology, Oviedo, Spain;(3)CHU Bicêtre- Universite Paris Saclay, Gastroenterology, Paris, France;(4)Aarhus University Hospital, Gastroenterology and Hepatology, Aarhus, Denmark;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Universitari Germans Trias i Pujol- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Barcelona, Spain;(7)La Fe University and Polytechnic Hospital- Health Research Institute La Fe, Gastroenterology, Valencia, Spain;(8)Bellvitge University Hospital, Gastroenterology, Barcelona, Spain;(9)Hospital de la Santa Creu i Sant Pau, Digestive Services, Barcelona, Spain;(10)Hospital Clinic- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Barcelona, Spain;(11)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(12)Universitary of Szeged, Medicine, Szeged, Hungary;(13)Medical Section- Copenhagen University Hospital Hvidovre, Gastrounit, Hvidovre, Denmark;(14)Biodonostia Health Research Institute- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Universidad del País Vasco UPV/EHU, Gastroenterology, San Sebastián, Spain;(15)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(16)University of Medicine and Pharmacy- Science and Tehnology "G E Palade" Tg.Mures, Gastroenterology, Târgu-Mureș, Romania;(17)University Hospital of Ioannina, Gastroenterology, Ioannina, Greece;(18)University Clinic Hospital Lozano Blesa- Institute for Health Research Aragón IIS Aragón, Gastroenterology, Zaragoza, Spain;(19)Azienda Ospedale Università di Padova AOUP- Department of Surgery- Oncology and Gastroenterology DiSCOG- University of Padua, Gastroenterology, Padua, Italy;(20)Servei d'Aparell Digestiu. Corporació Sanitària Universitària Parc Taulí- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Instituto de Salud Carlos III- Universitat Autònoma de Barcelona, Gastroenterology, Sabadell, Spain;(21)General University Hospital of Valencia, Digestive Diseases, Valencia, Spain;(22)Institute for Digestive Research- Lithuanian University of Health Sciences, Gastroenterology, Kaunas, Lithuania;(23)Guy's and St Thomas' Hospital, IBD Unit, London, United Kingdom;(24)Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom;(25)Universitair Medische Centra UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P779: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)ECCO’23 CopenhagenYear: 2023
Authors: Casellas Jorda, F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Muñoz, F.(6);
(1)Hospital Universitari Vall d'Hebron, Crohn-Colitis Care Unit UACC, Barcelona, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IIS-Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd., Madrid, Spain;(4)Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal;(5)Takeda Farmacéutica España, Medical Department, Madrid, Spain;(6)Complejo Asistencial Universitario de Salamanca, Digestive Service, Salamanca, Spain;
P780: Prognosis and optimal treatment for 5-aminosalicylic acid-intolerant patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Yaguchi, K.(1,2)*;Kinoshita, H.(1);Kunisaki, R.(1,2);Madarame, A.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Hama, T.(1);Onishi, M.(1);Kobayashi, K.(1);Shibui, S.(1);Toritani, K.(1);Nishida, D.(1);Matsubayashi, M.(1);Nakamori, Y.(1);Nishio, M.(1);Umezawa, S.(1);Ogashiwa, T.(1);Sasaki, T.(1);Fujii, A.(1);Kimura, H.(1);Kato, J.(3);Maeda, S.(2);
(1)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan;(2)Yokohama City University Graduate School of Medicine, Department of Gastroenterology, Yokohama, Japan;(3)Chiba University Graduate School of Medicine, Department of Gastroenterology, Chiba, Japan;
P781: Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING studyECCO’23 CopenhagenYear: 2023
Authors: Rubin, D.T.(1);Panés, J.(2);Torres, J.(3,4,5);Kobayashi, T.(6);Su, C.(7);Lawendy, N.(7);Modesto, I.(8);Segovia, M.(7,9);Gardiner, S.(8);Wang, W.(7);Vermeire, S.(10)*;
(1)-, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(2)Formerly Department of Gastroenterology, Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain;(3)Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal;(4)Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;(5)Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal;(6)Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Toyko, Japan;(7)-, Pfizer Inc, Collegeville- PA, United States;(8)-, Pfizer Inc, New York- NY, United States;(9)-, Rutgers University, New Brunswick- NJ, United States;(10)Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium;
P782: Ustekinumab in Ulcerative colitis: a real-life effectiveness study across multiple Belgian centers (SULTAN)ECCO’23 CopenhagenYear: 2023
Authors: Holvoet, T.(1)*;Truyens, M.(2);Reenaers, C.(3);Baert, F.(4);Vandenbranden, S.(5);Cremer, A.(6);Pouillon, L.(7);Dewint, P.(8);Van Moerkercke, W.(9);Rahier, J.F.(10);Vandermeulen, L.(11);Van Dongen, J.(12);Peeters, H.(13);Lambrecht, G.(14);Vijverman, A.(15);Lobaton, T.(16);
(1)VITAZ, Gastroenterology, Sint Niklaas, Belgium;(2)Ghent University Hospital, Gastroenterology, Ghent, Belgium;(3)CHU Liege, Gastroenterology, Liege, Belgium;(4)AZ Delta, Gastroenterology, Roeselaere, Belgium;(5)OLV Aalst, Gastroenterology, Aalst, Belgium;(6)Hôpital Erasme, Gastroenterology, Brussels, Belgium;(7)Imelda, Gastroenterology, Bonheiden, Belgium;(8)AZ Maria Middelares, Gastroenterlogy, Gent, Belgium;(9)AZ Groeninge, Gastroenterology, Kortrijk, Belgium;(10)CHU Namur, Gastroenterology, Namur, Belgium;(11)UZ Brussel, Gastroenterology, Brussel, Belgium;(12)AZ Sint Maarten, Gastroenterology, Mechelen, Belgium;(13)AZ Sint Lucas, Gastroenterology, Gent, Belgium;(14)AZ Damiaan, Gastroenterology, Oostende, Belgium;(15)CHR de la citadelle, Gastroenterology, Liege, Belgium;(16)Ghent University Hospital, Gastroenterology, Gent, Belgium;BIRD
